Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Expenses (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Operating Expenses for 13 consecutive years, with $141.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 4.26% year-over-year to $141.5 million, compared with a TTM value of $526.2 million through Dec 2025, up 13.83%, and an annual FY2025 reading of $526.2 million, up 13.83% over the prior year.
  • Operating Expenses was $141.5 million for Q4 2025 at Agios Pharmaceuticals, up from $129.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $141.5 million in Q4 2025 and bottomed at $91.2 million in Q3 2021.
  • Average Operating Expenses over 5 years is $109.4 million, with a median of $104.2 million recorded in 2021.
  • Peak annual rise in Operating Expenses hit 22.85% in 2021, while the deepest fall reached 27.1% in 2021.
  • Year by year, Operating Expenses stood at $104.8 million in 2021, then decreased by 1.28% to $103.5 million in 2022, then increased by 9.56% to $113.4 million in 2023, then grew by 19.75% to $135.8 million in 2024, then grew by 4.26% to $141.5 million in 2025.
  • Business Quant data shows Operating Expenses for AGIO at $141.5 million in Q4 2025, $129.7 million in Q3 2025, and $139.5 million in Q2 2025.